1
|
Gao Y, Zhang M, Sun G, Ma L, Nie J, Yuan Z, Liu Z, Cao Y, Li J, Liu Q, Ye S, Chen B, Song Y, Wang K, Ren Y, Ye G, Xu L, Liu S, Chen Q, Li W, Chen X, Fu P, Wei W, Guo B, Wang H, Cai Z, Du C, Wu Z, Zha X, Huang H, Xu J, Zhang C, Shi Y, Liu T, Liu S, Jiang Z, Lin Y. The features of male breast cancer in China: A real-world study. Breast 2024; 76:103762. [PMID: 38924994 PMCID: PMC11259957 DOI: 10.1016/j.breast.2024.103762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2024] [Revised: 06/17/2024] [Accepted: 06/21/2024] [Indexed: 06/28/2024] Open
Abstract
BACKGROUND Male breast cancer (MBC) is a rare disease. Although several large-scale studies have investigated MBC patients in other countries, the features of MBC patients in China have not been fully explored. This study aims to explore the features of Chinese MBC patients comprehensively. METHODS We retrospectively collected data of MBC patients from 36 centers in China. Overall survival (OS) was evaluated by the Kaplan-Meier method, log-rank test, and Cox regression analyses. Multivariate Cox analyses were used to identify independent prognostic factors of the patients. RESULTS In total, 1119 patients were included. The mean age at diagnosis was 60.9 years, and a significant extension over time was observed (P < 0.001). The majority of the patients (89.1 %) received mastectomy. Sentinel lymph node biopsy was performed in 7.8 % of the patients diagnosed in 2009 or earlier, and this percentage increased significantly to 38.8 % in 2020 or later (P < 0.001). The five-year OS rate for the population was 85.5 % [95 % confidence interval (CI), 82.8 %-88.4 %]. Multivariate Cox analysis identified taxane-based [T-based, hazard ratio (HR) = 0.32, 95 % CI, 0.13 to 0.78, P = 0.012] and anthracycline plus taxane-based (A + T-based, HR = 0.47, 95 % CI, 0.23 to 0.96, P = 0.037) regimens as independent protective factors for OS. However, the anthracycline-based regimen showed no significance in outcome (P = 0.175). CONCLUSION As the most extensive MBC study in China, we described the characteristics, treatment and prognosis of Chinese MBC population comprehensively. T-based and A + T-based regimens were protective factors for OS in these patients. More research is required for this population.
Collapse
Affiliation(s)
- Yuxuan Gao
- Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
| | - Mengmeng Zhang
- Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
| | - Gang Sun
- Department of Breast and Thyroid Surgery, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
| | - Li Ma
- Department of Breast Surgery, Hebei Provincial Tumor Hospital, Shijiazhuang, China.
| | - Jianyun Nie
- Breast Cancer Institute, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.
| | - Zhongyu Yuan
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
| | - Zhenzhen Liu
- Department of Breast Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
| | - Yali Cao
- Prevention and Cure Center of Breast Disease, The Third Hospital of Nanchang City, Nanchang, China.
| | - Jianbin Li
- The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
| | - Qiang Liu
- Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
| | - Songqing Ye
- Department of Tumor Surgery, Fujian Provincial Hospital, Fuzhou, China.
| | - Bo Chen
- The Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, China.
| | - Yuhua Song
- Breast Center B Ward, The Affiliated Hospital of Qingdao University, Qingdao, China.
| | - Kun Wang
- Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
| | - Yu Ren
- Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
| | - Guolin Ye
- Department of Breast Surgery, The First People's Hospital of Foshan, Foshan, China.
| | - Ling Xu
- Department of Thyroid and Breast Surgery, Peking University First Hospital, Beijing, China.
| | - Shu Liu
- Department of Breast Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
| | - Qianjun Chen
- Department of Breast Disease, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
| | - Weiwen Li
- Department of Breast, Jiangmen Central Hospital, Jiangmen, China.
| | - Xinxin Chen
- Department of Breast Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
| | - Peifen Fu
- Department of Breast Surgery, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
| | - Wei Wei
- Peking University Shenzhen Hospital, Shenzhen, China.
| | - Baoliang Guo
- Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin City, China.
| | - Hebing Wang
- Department of Breast Surgery, Affiliated Sanming First Hospital of Fujian Medical University, Sanming, China.
| | | | - Caiwen Du
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
| | - Zhiyong Wu
- Diagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou, China.
| | - Xiaoming Zha
- The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
| | - Heng Huang
- Department of Breast Oncology, Lianjiang Pepole's Hospital, Lianjiang, China.
| | - Juan Xu
- Guangdong Women and Children Hospital, Guangzhou, China.
| | - Chenglei Zhang
- Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, China.
| | - Yingying Shi
- Department of Breast Disease, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai City, China.
| | - Ting Liu
- Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
| | - Sihua Liu
- Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
| | - Zefei Jiang
- The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
| | - Ying Lin
- Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
| |
Collapse
|
3
|
Arzanova E, Mayrovitz HN. Male Breast Cancer: Treatment Trends, Reported Outcomes, and Suggested Recommendations. Cureus 2021; 13:e18337. [PMID: 34725599 PMCID: PMC8555756 DOI: 10.7759/cureus.18337] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Accepted: 09/27/2021] [Indexed: 12/13/2022] Open
Abstract
Male breast cancer (MBC) is unfamiliar to most men, and its optimal treatment options are not well recognized by many treating physicians. The lack of MBC specific clinical trials contributes to the limitations of understanding MBC specific pathology, treatment options, and outcomes. This state-of-affairs contribute to perpetuating the use of treatment methods derived from our existing knowledge of female breast cancer (FBC). Previous studies demonstrate that men are often undertreated or disproportionately treated using more invasive surgical procedures even in the early stages of MBC. The purpose of this investigation was to thoroughly discuss current MBC treatment options, provide an evidence-based summary of their outcomes, note recent improvements, discuss important considerations and recommendations. Our goal is to aid the treatment decision process for patients and treating physicians.
Collapse
Affiliation(s)
- Evelina Arzanova
- Osteopathic Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Davie, USA
| | - Harvey N Mayrovitz
- Medical Education, Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine, Davie, USA
| |
Collapse
|
4
|
Perry LM, Bateni SB, Sauder CAM. ASO Author Reflections: Deescalating Therapy for Older Men with Early Estrogen Receptor Positive Breast Cancer. Ann Surg Oncol 2020; 28:2472-2473. [PMID: 33169302 DOI: 10.1245/s10434-020-09357-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Accepted: 10/28/2020] [Indexed: 12/20/2022]
Affiliation(s)
- Lauren M Perry
- Division of Surgical Oncology, Department of Surgery, University of California, Davis Medical Center, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA
| | - Sarah B Bateni
- Division of Surgical Oncology, Department of Surgery, University of Toronto, Toronto, ON, Canada
| | - Candice A M Sauder
- Division of Surgical Oncology, Department of Surgery, University of California, Davis Medical Center, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.
| |
Collapse
|